Table 1:

Patient and Tumor Characteristics at Diagnosis and Failure

Characteristic	All N (%) / Median (Range)	No Re-RT N (%) / Median (Range)	Re-RT N (%) / Median (Range)
Age, years	7 (1.8–19)	6 (1.8–18)	9.9 (2–19)
Sex
Male	17 (74)	9 (39)	8 (35)
Female	6 (26)	2 (9)	4 (17)
Histology
Alveolar	7 (30)	1 (4)	6 (26)
Embryonal	16 (70)	10 (43)	6 (26)
Primary Site
Head and Neck Other	2 (9)	0	2 (9)
Parameningeal	8 (35)	4 (17)	4 (17)
Bladder/Prostate	6 (26)	3 (13)	3 (13)
Vagina	1 (4)	0	1 (4)
Extremity	3 (13)	1 (4)	2 (9)
Pelvis, unknown	1 (4)	1 (4)	0
Orbital	2 (9)	2 (9)	0
Initial Regional Nodal Involvement
Yes	7 (30)	4 (17)	3 (13)
No	16 (70)	7 (30)	9 (39)
Initial Risk Stratification
Low	4 (17.5)	2 (18.2)	2 (16.7)
Intermediate	16 (69.5)	8 (72.7)	8 (66.7)
High	3 (13)	1 (9)	2 (16.7)
Initial Oberlin Score
1	2 (8.7)	1 (9)	1 (8)
3	1 (4)	0	1 (8)
Initial IRSG Stage
1	7 (30)	3 (13)	4 (17)
2	1 (4)	1(4)	0
3	12 (52)	6 (26)	6 (26)
4	3 (13)	1 (4)	2 (9)
Initial IRSG Group
I	1 (4)	0	1 (4)
II	1 (4)	0	1 (4)
III	18 (78)	10 (43)	8 (35)
IV	3 (13)	1 (4)	2 (9)
Translocation Status
Absent	6 (26)	3 (13)	3 (13)
Present (PAX3 t(2:13) or PAX7 t(1:13))	7 (30)	2 (9)	5 (22)
None Available	10 (43)	6 (26)	4 (17)
Favorable Site
Yes	5 (22)	2 (9)	3 (13)
No	18 (78)	9 (39)	9 (39)
Time to 1st Failure from 1st RT course (months)	12 (10–22)	12 (9.4–15.5)	12.2 (11–36)
1st Failure Type
Local Only	13 (56.5)	8 (72.7)	5 (41.6)
Local + Regional	7 (30.4)	3 (27.3)	4 (33.3)
Local + Distant	2 (8.7)	0 (0)	2 (16.7)
Local + Regional + Distant	1 (4.3)	0 (0)	1 (8.3)

No Re-RT = unirradiated at relapse, Re-RT = re-irradiated at relapse, M = median, IRSG = International Rhabdomyosarcoma Study Group.